In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor

Journal of the National Cancer Institute

Volumn 91, Issue 2, 1999, Pages 163-168

  Le Coutre, Philipp ^a   Mologni, Luca ^a   Cleris, Loredana ^a   Marchesi, Edoardo ^a   Buchdunger, Elisabeth ^b   Giardini, Roberto ^a   Formelli, Franca ^a   Gambacorti Passerini, Carlo ^c,d  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b NOVARTIS PHARMA AG   (Switzerland)

^c SAN GERARDO HOSPITAL   (Italy)

^d Instituto Nuzionale Tumori   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; ONCOPROTEIN; PROTEIN BCR ABL TYROSINE KINASE INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

ACUTE LYMPHOCYTIC LEUKEMIA; ANIMAL CELL; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CHROMOSOME TRANSLOCATION 22; CHROMOSOME TRANSLOCATION 9; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG EFFICACY; ENZYME INHIBITION; FEMALE; GROWTH INHIBITION; HUMAN; HUMAN CELL; INTRAPERITONEAL DRUG ADMINISTRATION; LEUKEMIA CELL; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 0033585504     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/91.2.163     Document Type: Article

References (11)

1. Heisterkamp N, Stam K, Groffen J, de Klein A, Grosveld G. Structural organization of the bcr gene and its role in the Ph′ translocation. Nature 1985;315:758-61.
2. Barila D, Superti-Furga G. An intramolecular SH3-domain interaction regulates c-Abl activity. Nat Genet 1998;18:280-2.
3. Goga A, McLaughlin J, Afar DE, Saffran DC, Witte ON. Alternative signals to RAS for hematopoietic transformation by the BCR-ABL oncogene. Cell 1995;82:981-8.
4. Buchdunger E, Zimmermann J, Mett H, Meyer T, Muller M, Druker BJ, et al. Inhibition of the AbI protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res 1996;56:100-4.
5. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996;2:561-6.
6. Gambacorti-Passerini C, le Coutre P, Mologni L, Fanelli M, Bertazzoli C, Marchesi E, et al. Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis. Blood Cells Mol Dis 1997;23:380-94.
7. Deininger MW, Goldman JM, Lydon N, Melo JV. The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. Blood 1997;90: 3691-8.
8. Wang JC, Lapidot T, Cashman JD, Doedens M, Addy L, Sutherland DR, et al. High level engraftment of NOD/SCID mice by primitive normal and leukemic hematopoietic cells from patients with chronic myeloid leukemia in chronic phase. Blood 1998;91: 2406-14.
9. Kishi K. A new leukemia cell line with Philadelphia chromosome characterized as basophil precursors. Leuk Res 1985;9:381-90.
10. Okabe M, Kunieda Y, Nakane S, Kurosawa M, Itaya T, Vogler WR, et al. Establishment and characterization of a new Ph 1-positive chronic myeloid leukemia cell line MC3 with trilineage phenotype and an altered p53 gene. Leuk Lymphoma 1995;16:493-503.
11. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer 1976;35: 1-39.